{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:22:29Z","timestamp":1787595749147,"version":"build-2736575974"},"reference-count":38,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2025,1,2]]},"DOI":"10.1080\/14740338.2024.2348577","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T03:34:37Z","timestamp":1714361677000},"page":"59-68","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Safety of marketed biosimilar monoclonal antibody cancer treatments in the US: a disproportionality analysis using the food and drug administration adverse event reporting system (FAERS) database"],"prefix":"10.1080","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5648-2227","authenticated-orcid":false,"given":"Xiangzhong","family":"Xue","sequence":"first","affiliation":[{"name":"Auburn University Harrison College of Pharmacy","place":["Auburn, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4624-9963","authenticated-orcid":false,"given":"Jingjing","family":"Qian","sequence":"additional","affiliation":[{"name":"Auburn University Harrison College of Pharmacy","place":["Auburn, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"key":"e_1_3_7_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1249551"},{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.103915"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2015.03.018"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/11530830-000000000-00000"},{"key":"e_1_3_7_6_1","unstructured":"U.S. Food and Drug Administration. FDA and FTC collaborate to advance competition in the biologic marketplace [2023 Aug 11]. Available from: https:\/\/www.fda.gov\/news-events\/fda-voices\/fda-and-ftc-collaborate-advance-competition-biologic-marketplace"},{"key":"e_1_3_7_7_1","unstructured":"U.S. Food and Drug Administration. Biosimilars. cited 2022 Aug 11]. Available from: https:\/\/www.fda.gov\/drugs\/therapeutic-biologics-applications-bla\/biosimilars"},{"key":"e_1_3_7_8_1","unstructured":"Association for Accessible Medicines. The U.S. Generic & biosimilar medicines savings report 2022 [cited 2023 Aug 11]. Available from:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/accessiblemeds.org\/sites\/default\/files\/2022-09\/AAM-2022-Generic-Biosimilar-Medicines-Savings-Report.pdf"},{"key":"e_1_3_7_9_1","unstructured":"American Medical Association. Report: 2022 U.S. Generic and Biosimilar Medicines Savings Report 2022 [cited 2023 Aug 11]."},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0728"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01953.x"},{"key":"e_1_3_7_12_1","unstructured":"U.S. Food and Drug Administration. Biosimilar product information [2023 Aug 11]. Available from: https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220957079"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.07.015"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0588"},{"key":"e_1_3_7_16_1","first-page":"1","article-title":"Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States","volume":"9","author":"Xue X","year":"2023","unstructured":"Xue X, Truong B, Qian J. Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States. Expert Opin Biol Ther. 2023 Mar;9:1\u20139.","journal-title":"Expert Opin Biol Ther"},{"key":"e_1_3_7_17_1","unstructured":"US Food and Drug Administration. Questions and answers on FDA\u2019s adverse event reporting system (FAERS). 2018 [cited 2023 Aug 11]. Available from: https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers"},{"key":"e_1_3_7_18_1","unstructured":"U.S. Food and Drug Administration. Purple book: lists of licensed biological products with reference product exclusivity and biosimilarity or interchangeability evaluations 2020 [cited 2023 Aug 16]. Available from: https:\/\/www.fda.gov\/drugs\/therapeutic-biologics-applications-bla\/purple-book-lists-licensed-biological-products-reference-product-exclusivity-and-biosimilarity-or"},{"key":"e_1_3_7_19_1","unstructured":"U.S. Food and Drug Administration. Biosimilar product information 2022 [cited 2023 Aug 16]. Available from: https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information"},{"key":"e_1_3_7_20_1","unstructured":"U.S. Food and Drug Administration. Nonproprietary naming of biological products guidance for industry. 2019 [cited 2023 Aug 16]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/nonproprietary-naming-biological-products-guidance-industry"},{"key":"e_1_3_7_21_1","unstructured":"U.S. Food and Drug Administration. What is a serious adverse event? 2016 [cited 2023 Aug 16]. Available from: https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event"},{"key":"e_1_3_7_22_1","unstructured":"BioPortal. Medical dictionary for regulatory activities terminology (MedDRA) 2023 [cited 2023 Aug 16]. Available from: https:\/\/bioportal.bioontology.org\/ontologies\/MEDDRA"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.773135"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5624"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-017-0574-4"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02510.x"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00059-X"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520949986"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1562905"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221086222"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2702"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.83"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2011.13243"},{"key":"e_1_3_7_34_1","unstructured":"A post-marketing surveillance to assess the safety and effectiveness of Zirabev in domestic patients with various cancer. 2022 [cited 2023 Aug 16]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04889495?intr=Zirabev&rank=1"},{"key":"e_1_3_7_35_1","unstructured":"Trastuzumab\u2010Induced maculopapular rash: fact or fiction? 2014 [2023 Aug 11]. Available from: https:\/\/shmabstracts.org\/abstract\/trastuzumabinduced-maculopapular-rash-fact-or-fiction\/"},{"key":"e_1_3_7_36_1","unstructured":"Food and Drug Administration. Highlights of prescribing information. 2019 [cited 2023 Aug 16]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761081s000lbl.pdf"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.4103\/jpgm.JPGM_109_19"},{"key":"e_1_3_7_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0256-z"},{"key":"e_1_3_7_39_1","unstructured":"U.S. FOOD & DRUG ADMINISTRATION. Review and approval. Available from: https:\/\/www.fda.gov\/drugs\/biosimilars\/review-and-approval"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2024.2348577","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T06:50:35Z","timestamp":1776754235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2024.2348577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,2]]}},"alternative-id":["10.1080\/14740338.2024.2348577"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2024.2348577","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-10-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}